S&P 500   2,584.59 (-1.60%)
DOW   21,917.16 (-1.84%)
QQQ   190.40 (-0.85%)
AAPL   254.29 (-0.20%)
FB   166.80 (+0.51%)
MSFT   157.71 (-1.57%)
GOOGL   1,161.95 (+1.36%)
AMZN   1,949.72 (-0.72%)
CGC   14.42 (-0.28%)
NVDA   263.60 (-0.75%)
BABA   194.48 (+1.68%)
MU   42.06 (-5.53%)
GE   7.94 (+0.63%)
TSLA   524.00 (+4.36%)
AMD   45.48 (-4.97%)
T   29.15 (-3.57%)
ACB   0.91 (+2.26%)
F   4.83 (-3.98%)
NFLX   375.50 (+1.22%)
BAC   21.23 (-3.68%)
GILD   74.76 (-1.54%)
PRI   88.48 (-2.46%)
DIS   96.60 (-3.21%)
S&P 500   2,584.59 (-1.60%)
DOW   21,917.16 (-1.84%)
QQQ   190.40 (-0.85%)
AAPL   254.29 (-0.20%)
FB   166.80 (+0.51%)
MSFT   157.71 (-1.57%)
GOOGL   1,161.95 (+1.36%)
AMZN   1,949.72 (-0.72%)
CGC   14.42 (-0.28%)
NVDA   263.60 (-0.75%)
BABA   194.48 (+1.68%)
MU   42.06 (-5.53%)
GE   7.94 (+0.63%)
TSLA   524.00 (+4.36%)
AMD   45.48 (-4.97%)
T   29.15 (-3.57%)
ACB   0.91 (+2.26%)
F   4.83 (-3.98%)
NFLX   375.50 (+1.22%)
BAC   21.23 (-3.68%)
GILD   74.76 (-1.54%)
PRI   88.48 (-2.46%)
DIS   96.60 (-3.21%)
S&P 500   2,584.59 (-1.60%)
DOW   21,917.16 (-1.84%)
QQQ   190.40 (-0.85%)
AAPL   254.29 (-0.20%)
FB   166.80 (+0.51%)
MSFT   157.71 (-1.57%)
GOOGL   1,161.95 (+1.36%)
AMZN   1,949.72 (-0.72%)
CGC   14.42 (-0.28%)
NVDA   263.60 (-0.75%)
BABA   194.48 (+1.68%)
MU   42.06 (-5.53%)
GE   7.94 (+0.63%)
TSLA   524.00 (+4.36%)
AMD   45.48 (-4.97%)
T   29.15 (-3.57%)
ACB   0.91 (+2.26%)
F   4.83 (-3.98%)
NFLX   375.50 (+1.22%)
BAC   21.23 (-3.68%)
GILD   74.76 (-1.54%)
PRI   88.48 (-2.46%)
DIS   96.60 (-3.21%)
S&P 500   2,584.59 (-1.60%)
DOW   21,917.16 (-1.84%)
QQQ   190.40 (-0.85%)
AAPL   254.29 (-0.20%)
FB   166.80 (+0.51%)
MSFT   157.71 (-1.57%)
GOOGL   1,161.95 (+1.36%)
AMZN   1,949.72 (-0.72%)
CGC   14.42 (-0.28%)
NVDA   263.60 (-0.75%)
BABA   194.48 (+1.68%)
MU   42.06 (-5.53%)
GE   7.94 (+0.63%)
TSLA   524.00 (+4.36%)
AMD   45.48 (-4.97%)
T   29.15 (-3.57%)
ACB   0.91 (+2.26%)
F   4.83 (-3.98%)
NFLX   375.50 (+1.22%)
BAC   21.23 (-3.68%)
GILD   74.76 (-1.54%)
PRI   88.48 (-2.46%)
DIS   96.60 (-3.21%)
Log in

NASDAQ:CBIO - Catalyst Biosciences Stock Price, Forecast & News

$4.37
-0.12 (-2.67 %)
(As of 03/31/2020 04:00 PM ET)
Today's Range
$4.19
Now: $4.37
$4.71
50-Day Range
$3.50
MA: $5.65
$8.51
52-Week Range
$3.43
Now: $4.37
$10.84
Volume114,400 shs
Average Volume284,597 shs
Market Capitalization$52.78 million
P/E RatioN/A
Dividend YieldN/A
Beta2.24
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors. The company is also developing Dalcinonacog alfa, a Factor IX drug, which has completed enrollment of a Phase I/II subcutaneous dosing trial for the prophylactic treatment of individuals with hemophilia B; CB 2679d-GT, a FIX gene therapy for the treatment of hemophilia B; and CB 2782, an anti-C3 protease program for the treatment of dry age-related macular degeneration (AMD), as well as CB 1965a, a Factor Xa therapeutic program used as a universal procoagulant. Catalyst Biosciences, Inc. has collaboration agreement with Pfizer, Inc. for the development of human Factor VIIa products; and ISU Abxis. The company has strategic research collaboration with Mosaic Biosciences, Inc. to develop intravitreal anti-complement factor 3 products for the treatment of dry AMD and other retinal diseases. The company was founded in 2002 and is headquartered in South San Francisco, California.
Read More
Catalyst Biosciences logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CBIO
CUSIP87611R30
Phone650-871-0761

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10,000.00
Book Value$5.68 per share

Profitability

Net Income$-55,180,000.00

Miscellaneous

Employees21
Market Cap$52.78 million
Next Earnings Date5/7/2020 (Estimated)
OptionableOptionable

Receive CBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for CBIO and its competitors with MarketBeat's FREE daily newsletter.


Catalyst Biosciences (NASDAQ:CBIO) Frequently Asked Questions

How has Catalyst Biosciences' stock been impacted by COVID-19 (Coronavirus)?

Catalyst Biosciences' stock was trading at $4.83 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CBIO stock has decreased by 9.5% and is now trading at $4.37. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Catalyst Biosciences?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalyst Biosciences in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Catalyst Biosciences.

When is Catalyst Biosciences' next earnings date?

Catalyst Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for Catalyst Biosciences.

How were Catalyst Biosciences' earnings last quarter?

Catalyst Biosciences Inc (NASDAQ:CBIO) announced its earnings results on Thursday, February, 20th. The biopharmaceutical company reported ($1.23) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($1.23). View Catalyst Biosciences' earnings history.

When did Catalyst Biosciences' stock split? How did Catalyst Biosciences' stock split work?

Catalyst Biosciences's stock reverse split on Monday, February 13th 2017. The 1-15 reverse split was announced on Friday, February 10th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 10th 2017. An investor that had 100 shares of Catalyst Biosciences stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for CBIO?

1 brokers have issued 1-year price objectives for Catalyst Biosciences' shares. Their forecasts range from $25.00 to $25.00. On average, they expect Catalyst Biosciences' share price to reach $25.00 in the next twelve months. This suggests a possible upside of 472.1% from the stock's current price. View analysts' price targets for Catalyst Biosciences.

Has Catalyst Biosciences been receiving favorable news coverage?

News headlines about CBIO stock have trended positive this week, according to InfoTrie. The research firm scores the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Catalyst Biosciences earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutCatalyst Biosciences.

Who are some of Catalyst Biosciences' key competitors?

What other stocks do shareholders of Catalyst Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Biosciences investors own include Baozun (BZUN), Inovio Pharmaceuticals (INO), NovaBay Pharmaceuticals (NBY), Celsion (CLSN), Amarin (AMRN), Synergy Pharmaceuticals (SGYP), Sarepta Therapeutics (SRPT), Catalyst Pharmaceuticals (CPRX), Novavax (NVAX) and Sangamo Therapeutics (SGMO).

Who are Catalyst Biosciences' key executives?

Catalyst Biosciences' management team includes the following people:
  • Dr. Nassim Usman, Pres, CEO & Director (Age 59)
  • Mr. Fletcher Payne, Chief Financial Officer (Age 56)
  • Dr. Howard Levy, Chief Medical Officer (Age 65)
  • Dr. Charles S. Craik, Co-Founder & Chairman of Scientific Advisory Board
  • Mr. Andrew Hetherington M.B.A., Sr. VP of Technical Operations

What is Catalyst Biosciences' stock symbol?

Catalyst Biosciences trades on the NASDAQ under the ticker symbol "CBIO."

How do I buy shares of Catalyst Biosciences?

Shares of CBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Catalyst Biosciences' stock price today?

One share of CBIO stock can currently be purchased for approximately $4.37.

How big of a company is Catalyst Biosciences?

Catalyst Biosciences has a market capitalization of $52.78 million and generates $10,000.00 in revenue each year. The biopharmaceutical company earns $-55,180,000.00 in net income (profit) each year or ($4.60) on an earnings per share basis. Catalyst Biosciences employs 21 workers across the globe. View additional information about Catalyst Biosciences.

What is Catalyst Biosciences' official website?

The official website for Catalyst Biosciences is http://www.catalystbiosciences.com/.

How can I contact Catalyst Biosciences?

Catalyst Biosciences' mailing address is 611 GATEWAY BLVD. SUITE 710, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-871-0761 or via email at [email protected]


MarketBeat Community Rating for Catalyst Biosciences (NASDAQ CBIO)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  265 (Vote Outperform)
Underperform Votes:  259 (Vote Underperform)
Total Votes:  524
MarketBeat's community ratings are surveys of what our community members think about Catalyst Biosciences and other stocks. Vote "Outperform" if you believe CBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/31/2020 by MarketBeat.com Staff

Featured Article: S&P/ASX 200 Index

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel